Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Transdermally applied scopolamine does not impair psychomotor performance (1984)
    Springer
    Psychopharmacology 83 (1984), S. 397-398 
    Details
    ISSN: 1432-2072
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Conclusion These results demonstrate that vigilance and sensorimotor abilities during continuous transdermal administration of scopolamine are not impaired. This is due to the dose of scopolamine being high enough to evoke an antiemetic effect but with minimal elicitation of undersired side effects. Wesnes and Warburton (1984), who used two oral doses in a pulse mode, showed either no effect on a rapid visual information-processing performance task (0.6 mg scopolamine) or a nearly 20% decrease in psychomotor performance (1.2 mg scopolamine) 30 min after drug intake. This is consistent with data from a recent publication (Muir and Metcalfe 1983) showing peak plasma concentrations after an oral dose of 415 μg scopolamine at approximately 30 min. Such peak concentrations are know to be responsible for unpleasant CNS side effects such as drowsiness, giddiness, confusion, and memory disturbancies (Shaw and Urquart 1980). The conclusion of Wesnes and Warburton that “the effects of scopolamine are... of relevance for example to sea-borne personnel engaged in tasks requiring sustained mental alertness” holds true only for scopolamine given in a pulse mode butnot for TTS-scopolamine.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00428554
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Clinical pharmacology of the new COMT inhibitor CGP 28 014 (1993)
    Springer
    Neurochemical research 18 (1993), S. 1163-1167 
    Details
    ISSN: 1573-6903
    Keywords: CGP 28 014 ; COMT inhibition ; isoquinoline excretion ; 3-O-methyldopa ; DOPAC test
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract CGP 28 014 is a specific inhibitor of catechol-O-methyltransferase (COMT) in vivo. In humans, the inhibition was assessed by measuring urinary excretion of isoquinolines and with the levodopa test. Following administration of CGP 28 014, urinary excretion of isoquinolines was significantly increased. In rats, CGP 28 014 reduced plasma and striatal concentrations of 3-O-methyldopa (30MD) in a dose-dependent manner. Acute and subchronic administration of CGP 28 014 alone or in combination with the peripherally acting decarboxylase inhibitor benserazide decreased plasma 30MD as an index of COMT inhibition by about 50%. There seems to be a close relationship between the time-course of plasma concentrations of CGP 28 014 and the extent of COMT inhibition assessed by the 30MD/DOPA ratio in plasma.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00978368
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...